Mahidol University and Celtac Co., Ltd. Launch Fibroblast Gen II, Advancing Thailand’s Future of Regenerative Medicine
Bangkok, Thailand – June 15, 2026 – Mahidol University and Celtac Co., Ltd. announced a strategic collaboration and the launch of Gen II Autologous Fibroblast Cell Technology under the theme “The Future of Autologous Fibroblast Cell Therapy,” marking another significant milestone in Thailand’s advancement of regenerative medicine, personalized healthcare, and medical innovation.
Bangkok, Thailand – Mahidol University and Celtac Co., Ltd. announced a strategic collaboration and the launch of Gen II Autologous Fibroblast Cell Technology under the theme “The Future of Autologous Fibroblast Cell Therapy,” marking another significant milestone in Thailand’s advancement of regenerative medicine, personalized healthcare, and medical innovation.
The event was held at Prince Mahidol Hall, Mahidol University, Salaya, and was presided over by Prof. Piyamitr Sritara, MD, FRCP President of Mahidol University. Joining the event were Prof.Apichat Asavamongkolkul,M.D. Dean of the Faculty of Medicine Siriraj Hospital. Asst. Prof. Patana Teng-umnuay Ph.D., M.D., representing Celtac Co., Ltd. Prof. Dr Rungsima Wanitphakdeedecha, M.D., Head of the Department of Dermatology, Faculty of Medicine Siriraj Hospital; Prof. Uraiwan Panich, M.D., Ph.D., Department of Pharmacology, Faculty of Medicine Siriraj Hospital; and Associate Professor Viriya Taecharungroj, Ph.D., Director of the Institute for Technology and Innovation Management (iNT), Mahidol University.
A key highlight of the event was the signing of a technology licensing agreement between Mahidol University and Celtac Co., Ltd. for the commercialization and further development of Gen II Autologous Fibroblast Cell Technology. The partnership builds upon years of collaboration that began with the transfer of Gen I technology and has now evolved into the next generation of innovation.
The technology utilizes a patient’s own fibroblast cells, which are cultured and developed through advanced laboratory processes. The platform is designed to support the growing field of Personalized Medicine and future applications in Regenerative Medicine, based on scientific research and intellectual property developed by the Faculty of Medicine Siriraj Hospital, Mahidol University.
The event also marked the official launch of the “SiRiGevity” brand and trademark, representing a successful example of translating academic research and innovation into practical commercial applications. The initiative highlights Thailand’s growing capability to bridge scientific discovery with industry adoption and healthcare innovation.
Mahidol University’s Institute for Technology and Innovation Management (iNT) has played a crucial role in facilitating technology transfer, intellectual property management, and partnerships with domestic and international industry stakeholders. These efforts aim to expand access to Thai medical innovations while maintaining internationally recognized standards of quality and safety.
Following the signing ceremony, an Executive Panel Discussion titled “The Future of Autologous Fibroblast Cell Therapy” brought together leading experts to discuss emerging trends in regenerative medicine, personalized healthcare, and Thailand’s opportunities to become a regional hub for advanced medical technologies.
Panelists emphasized that the development of Gen II Fibroblast Cell Technology reflects not only scientific and medical progress but also the capability of Thai researchers to create innovations with real-world applications. The technology represents a model for translating research into practical healthcare solutions that can contribute to improved quality of life and support the growth of Thailand’s future medical industry.
The collaboration between Mahidol University and Celtac Co., Ltd. is expected to strengthen Thailand’s position in advanced medical innovation, promote the development of next-generation healthcare industries, and generate sustainable economic and social value. The initiative aligns with Mahidol University’s mission as the “Wisdom of the Land” and its commitment to advancing research, innovation, and technology transfer for the benefit of society and the global healthcare community.
As regenerative medicine and personalized healthcare continue to gain international attention, the launch of Gen II Fibroblast Cell Technology demonstrates Thailand’s growing potential to contribute to the future of advanced medical science and innovation on the global stage.
Source :
Articles in this category are written by our editorial team to keep you informed about the latest healthcare and medical tourism news.
